Patient Safety

CMA e-Panel Survey Reveals Drug Cost Transparency Remains Hazy Among Canadian Doctors

CMA e-Panel Survey Reveals Drug Cost Transparency Remains Hazy Among Canadian Doctors

In the continuing efforts of Dr. Gorfinkel's campaign to mandate drug cost transparency and better Pharmacare for Canadians, some headway has been made with recent research.

Owen Adams, the Chief Policy Advisor at the Canadian Medical Association, recently forwarded the results of a survey of 3, 276 e-Panel members. This document provides a current overview of the doctors' awareness of costs of prescription medications. This data has been analyzed, summarized and made public on the CMA's website on November 13, 2018.

The findings serve as validation to the ongoing lack of knowledge by physicians of drug costs. Here are a few of the highlights: